Insights from the 2022 Benelux Private Equity & Venture Capital Breakfast

On September 22nd, 2022, senior decision-makers from private equity, financial institutions, advisory firms and holding companies gathered at the CMS headquarters in Amsterdam to discuss industry trends and exchange opinions. 

The panel was moderated by Mark Ziekman – Partner, Corporate/M&A, CMS and Poul Pedersen – Executive Chairman of Pedersen & Partners. Lively debate insights were provided by the panel members: 

  • Joost Heeremans – Partner, Rivean Capital
  • Erwin de Jong – Partner, Dutch Mezzanine Fund
  • Peter van Leersum – Partner, H2 Equity Partners
  • Jeroen Lenssen – Senior Director, Riverside
  • Taco Rietveld – Partner, RB Family Capital
  • Yvonne Rooijakkers – Head of Fund & Co-investments, Rabo Investments

Pedersen & Partners summarised the key takeaways from the debate as follows:

  • The Benelux M&A market has slowed down in the last quarter.
  • The deal environment is difficult due to multiple external factors including inflation, supply chain issues, the war in Ukraine, and a talent shortage which impact both portfolio firms and new investment activities.
  • Valuations are going down, and deals are not being concluded at the usual speed.
  • There is lot of dry powder left from earlier fundraising, so markets will improve in the future.
  • Banks have become reluctant to provide leverage. This is an opportunity for debt funds.
  • Exit is getting more difficult, but US-based buyers seem to be interested in buying European firms supported by the strong dollar.
  • It has become harder for technology firms and technology-focused funds to raise money in recent months, and valuations have come down significantly. 
  • Portfolio management continues to grow more professional, including well-structured plans for ESG, internationalisation, etc.
  • The Benelux PE market is crowded, with lots of funds operating in a small market. A certain amount of consolidation can be expected, as new fund managers find it hard to raise money right now.
     

Insights from the 2022 Austrian / CEE Private Equity & Venture Capital Breakfast

On May 17th, 2022, approximately 100 senior decision-makers from private equity, financial institutions, advisory firms and holding companies gathered at the CMS Reich-Rohrwig Hainz headquarters in Vienna to discuss industry trends and exchange opinions.

The event had been postponed twice due to COVID-19, so participation was enthusiastic and energised.

Insights from the 2022 Austrian / CEE Private Equity & Venture Capital Breakfast

The panels were moderated by Alexander Rakosi, Partner, CMS Reich-Rohrwig Hainz and Poul Pedersen, Executive Chairman of Pedersen & Partners. Lively debate insights were provided by the panel members:

  • Markus Lang – Partner, Speedinvest
  • Pekka Mäki – Managing Partner, 3TS Capital Partners
  • Farsin Yadegardjam – Partner, Co-Investor/EVP Capital
  • Philipp Freyschlag – Director, Bregal Unternehmerkapital
  • Gernot Hofer – Board Member, Invest AG;
  • Karl Lankmayr – Managing Director, AG Capital
  • Niklas Pichler – Managing Partner, BlackPeak Capital
  • Klaus Vukovich – Managing Partner, Alantra Austria & CEE

Katharina Kaiser, Client Partner & Country Manager for Austria at Pedersen & Partners summarised the key takeaways from the debate as follows:

  • While there is potential for further growth, the last 12 months have seen very positive developments for Austrian private equity funds. New funds have been raised, and large deals have been completed by local PE players.
  • The M&A and private equity market has been active in 2021 and Q1 2022, but most experts now forecast a slowdown.
  • It has become harder for technology firms and technology-focused funds to raise money in recent months, and valuations have come down significantly. However, well-funded portfolio firms can take advantage via add-on acquisitions.
  • Fund managers and portfolio firms are skilled at adapting to external events, such as the war in Ukraine, supply chain issues, inflation, and interest rates. For example, there is a preference for investing in firms that have the bargaining power to increase prices.
  • Portfolio management continues to grow more professional, including well-structured plans for securing the best leadership team, ESG, digitalisation, internationalisation, etc.

 

Insights from the 2022 Italian Private Equity Breakfast, hosted by Pedersen & Partners and CMS Adonnino Ascoli & Cavasola Scamoni

On May 3rd, 2022, senior decision makers from private equity, financial institutions, advisory firms and holding companies gathered at the Hotel Principe di Savoia in Milan to discuss industry trends and exchange opinions.

The keynote address was given by Anna Gervasoni, Chief Executive, AIFI (Italian Private Equity, Venture Capital and Private Debt Association). Ms. Gervasoni described the current PE sector in detail, with incoming funds from foreign and domestic LPs, and from newcomers such as pension funds, insurance companies, family offices, wealth management, and retail banks.

Insights from the 2022 Italian Private Equity Breakfast, hosted by Pedersen & Partners and CMS Adonnino Ascoli & Cavasola Scamoni

The panel was moderated by Paolo Scarduelli CMS Partners and introduced by Duncan Weston, CMS Executive Partner and Poul Pedersen, Executive Chairman of Pedersen & Partners. Contributors included:

  • Arabella Caporello – Partner, L Catterton Europe
  • Gianpaolo Di Dio – Chief Investment Officer, Senior Partner, Fondo Italiano d’Investimento
  • Raffaele Legnani – Managing Director, H.I.G. European Capital Partners
  • Guido Lorenzi – Partner, QuattroR
  • Marco Samaja – Managing Director, Lazard
  • Constantin Terzago – Managing Director, Mutares
  • Massimo Trentino – Partner, CMS.

Bruno Pastore, Client Partner & Country Manager for Italy at Pedersen & Partners summarised the key takeaways from the lively debate as follows:

  • The M&A market registered record numbers in 2021, although 2022 and beyond could see a slowdown with less IPO and more PE-secondary.
  • Small is no longer beautiful. “Buy & Build” is now the way to create value, and to improve the image of PE in the eyes of entrepreneurs – as partners rather than vulture funds.
  • A new Private Equity way forward is to invest in companies with financial stress and high debts, as a sort of de-leverage MBO.
  • Holding companies are investing in distressed companies and creating value through "ad-hoc" interventions.
  • The paramount importance of the human factor and the need for correct management assessment – where possible, this should happen before the investment, not after it.
  • New normative requirements will influence due diligence and target company management.
  • A more institutional approach is needed for “Buy & Build” value creation and compliance to ESG.

Despite many uncertain external factors such as the war in Ukraine, CV19, supply chain issues, inflation and a recent slowdown in deals, the entire panel had an optimistic outlook for 2022 and beyond.

Venture Capital Discussions: Bridging Technology and Healthcare

At the beginning of March 2021, the Pedersen & Partners Private Equity Practice Team and the Healthcare & Life Sciences Practice Team had the pleasure of jointly welcoming Andrew Thompson, a Silicon Valley entrepreneurial leader who has been a frequent presenter for the World Economic Forum.

Recognised as a thought leader in Healthcare and Technology, Mr. Thompson has raised over $750 million in private, public and corporate capital over the course of his career in his capacity of Founder and Chief Executive.

The team enjoyed a lively and inspiring discussion, and discussed several topics at length, including Mr. Thompson’s insights on bridging the potential of technology with the practice of healthcare.

We share a summary of the findings below, while expressing our sincere gratitude to Mr. Thompson for his valuable insights.

The healthcare challenge

At least half of the world’s population do not have access to basic healthcare. Every year, about 100 million people are pushed into extreme poverty due to out-of-pocket health expenses. Population growth, an increasing number of patients with chronic diseases, and the need to provide new, innovative and affordable treatments are just a few hurdles countries must overcome. Achieving global access to healthcare will require a fundamental shift in the way resources are allocated.

Technology drives a fundamental change

More technologists are working today than they have been over the rest of history combined, so change is happening fast. If you want to know what is going to fundamentally shift the allocation of resources over the next 10 years, it’s a good idea to look back at the last 100 years. The mobile internet and associated digital technologies are a transformative shift; these technologies are remaking all our lives socially, politically, economically, and militarily. They are an opportunity to create a fundamental shift in the way resources are allocated.

The tech industry has created a fundamental shift in the way computing resources are allocated. There are three keys to making this happen:

  • Consumerise – a cell phone, not a workstation; more computing power is now owned by consumers than by governments and corporations combined
  • Systematise – tech ecosystem that enables a seamless experience; all the complexity is dealt with by producers, not by consumers
  • Globalise – sell to everyone, not just rich people in rich countries; most people who own a mobile device make less than $10 a day

Changing the healthcare business model to serve customers Different approaches: US, Europe and Emerging Economies

The key to a fundamental shift in healthcare is what happens in the USA – the most advanced and expensive system, serving as a benchmark for the rest of the world. We don’t have a healthcare system. We have a sick care system. The system was designed in the last century to deal with the major problems of the time: acute disease and trauma. It does the job for which it was designed quite well, and it uses the best technology of the 20th century. It is driven by revenue: producers, payers, providers, and politicians all like healthcare inflation. The only people who would like healthcare to cost less are patients, but they are not part of the healthcare business model in the USA.

Covid may accelerate the creation of a healthcare system that makes use of the best technologies we have today. The potential of a building where you plug in to electricity can be magnified by the power of a mobile device where you log on to the internet. The capacity and expertise of people with knowledge in their heads is potentially massively extended by software and servers with intelligence in the cloud. Products designed to be safe in everybody and work in somebody could become services – tailored to you, your genes and your lifestyle, delivered where you live, work, and play, in ways that you see, measure and understand, at a price you can afford to pay.

European healthcare is also a sick care system, largely government-funded, where the key economic drivers are cost saving and budget compliance. The challenge is again incumbency and creating a change in purpose (from sick care to healthcare) in scaled human systems that is very hard to achieve.

Then there are emerging markets – will people in China see things differently? Potentially, but only if they don’t use business models that are based on the tools of the last century. The problem with healthcare and how it works in many emerging markets (India for instance) is that they try to replicate the US healthcare system in many ways, and thus create another magnificent dinosaur-style system that no one can afford. The opportunity for India is to leapfrog into a very different healthcare market that is consumer-driven, based on mobile phones, and addresses the basic and most obvious healthcare needs. The opportunity is not so much about China versus America or India, but about a generation of young, smart people who see the discontinuity, and who see new business models that can fundamentally change the way in which large industries work. Alongside that, governments can contribute through smart regulatory policy that makes it possible for these new companies to succeed.

Adding value as a VC

It is important to figure out what questions you are going to ask and in what order: Does this make a difference for a patient? Will this make money? Adding value as a VC is backing technology that makes a difference for patients, and then working to ensure there is a business model that will make money. It is not backing technology that will make money, and then working to ensure it makes a difference for patients.

Raising Money

Raising money for an early-stage company requires a strong narrative – a story. VCs are some of the most patient, open-minded and least opinionated people you will ever meet. With that in mind, I always encourage folks to realise they have 30 seconds to get them engaged. A great healthcare pitch is:

  • This is what I’ve got: a unique technology, a great team, a massive market opportunity, and a fast path into the market
  • This is why it’s important: it meets a major clinical need and we have figured out how to align economic incentives for patient, provider, and payer
  • This is why you should invest now: we are executing rapidly and we will hit these value driving milestones soon.

 

Andrew Thompson

Guest Speaker:

Andrew Thompson,

Managing Director and Co-Founder, Spring Ridge Ventures

 

Alvaro Arias

Moderator:

Alvaro Arias,

Partner, Global Head of Private Equity Practice Group

 

 

Lydia Van Der Meulen

Guest speaker introduction:

Lydia van der Meulen,

Client Partner, Global Head of Life Sciences & Healthcare Practice Group

 

 

Beryl Chu

Guest speaker introduction:

Beryl Chu,

Client Partner, Private Equity Practice Group

 

 

Nurturing Nest for the Future Unicorns

Riga, Latvia – Evita Lune, Partner for Global Digital Economy at Pedersen & Partners interviewed Marili Merendi, Associate at Karma Ventures.

Marili Merendi is an Associate at karma.vc — an early stage venture capital firm specialized in late seed and series A investments in Europe’s most promising tech startups. At karma.vc Marili covers deal sourcing, due diligence, financial valuation, and all-round portfolio management tasks.
Her previous experience is in finance and investment advisory positions at various international organizations such as: Kraft Foods, UBS Investment Bank and UBS Wealth Management in Zürich. Marili holds an MSc in Business Economics from the University of Amsterdam, complemented by the extended studies in the US, Norway, and Switzerland. She is a music fan and outdoor sports enthusiast.
 
 
Evita: Let’s start by understanding, what is your job about at Karma?
 
Marili: To tell you this, let me briefly introduce Karma Ventures. We are a Pan-European venture capital fund operating out of Estonia. We invest in early-stage technology companies all over Europe, and since our establishment three years ago we’ve done eleven investments, six of which are in the Baltics:  one is in Riga - Sonarworks,  two in Sweden, two in Finland and one in the UK. Our focus is on startups that build unique tech heavy solutions and that solve big customer problems. We’ve noticed that our preference is mostly towards B2B software startups.
 
I work on deal sourcing and the initial analysis of the deal and company characteristics. Once we decide to proceed with a deal, my tasks include working with my team by preparing due diligence and documentation. When we have closed the deal, I continue to actively work with portfolio companies. However, while part of my job is facilitating the analytically structured process in working with startups, the other part is trying to enable the founders to leverage their own potential through collective knowledge sharing and open discussion with them.
 
With regard to Karma’s value add, this is a question to our portfolio companies as they are the true judges here. From practical aspects we typically focus on the business stage where there is an early evidence of product-market fit of the solution, and where the company is about to build the scaling business processes and culture for fast acceleration. What it usually means, is that we work together with the founders on business strategy and recruiting, as we believe that one can only scale by hiring great people that bring true value and know-how on scaling and making a company stronger and better. We don’t expect the founders to be experts at this, but we expect them to be able to attract the talent that have the necessary expertise.
"We believe that one can only scale by hiring great people that bring true value and know-how on scaling and making a company stronger and better.”
 
Evita: Can you share a bit more about the investments that you have made? You mentioned that there are 11 different companies, half or which are in the Baltics mainly in B2B field.
 
Marili: Sure. Up to date we have mostly invested in companies targeting B2B customers, but we also have a few marketplaces that bring together the supply and demand side. For example, in Lithuania we invested in CGTrader, which is a 3D model marketplace; in Estonia we invested in HR marketplace/platform MeetFrank that brings together people looking for an interesting job and companies looking for great talent while both may not explicitly state this interest. Regarding other companies in our portfolio, we have investments in developer tools such as AppGyver and Plumbr; machine intelligence based emotion recognition software provider Realeyes; in Riga we have investment in Sonarworks, which is a software for headphone sound calibration enabling music fans to hear more authentic sound; we also have big data analytics platform SpectX; cloud based automated computational fluid dynamics software provider Adaptive Simulations; legal tech leader TrademarkNow; and finally B2B as well as consumer focused non-intrusive home security provider Minut from Sweden.
 
Evita: What about the technology side of these deals and in general, reviewing potential investments, how do you manage to judge if this will work or not?
 
Marili: When we look at an opportunity, we consider several inputs, such as market trends: what is trending globally, where the consumers and the businesses are heading to and what business models are in place. Then we analyse the competition: what type of solutions the competitors provide, how many alternatives are out there for the customer to consider, the funding of the competition, etc. All this gives us a fairly good indication of where the innovation and its financing is heading to. We also conduct reference checks with the customers and business partners of the startup under evaluation, meaning that we directly ask customers how relevant certain technology is for them and how it impacts their business. We do not conduct technical due diligence in house, but rather get this input from customer references in order to build the thesis whether the startup is on a path to become a global player. We tend to take customer input seriously as it is fair to assume that before they decided to pay for a solution, they looked at various alternatives, thus providing us with a really good comparison and understanding of the provided value. Then, of course, we look at the team trying to estimate the existing skill set as well as the potential to adapt to life’s challenges that one encounters while trying to build a unicorn.
 
Additionally, unlike many other funds we have a tech advisory meeting with the startups, where two of the Skype founding engineers — Jaan Tallinn and Ahti Heinla — bring additional input to our decision making process. We are lucky to leverage their know-how and global experience of building and developing Skype, putting together and investing in a portfolio of global technology companies previously, and currently being active in an international scene of thriving technology innovation.
 
Read the whole interview here.
Evita Lune is a Partner who drives the firm’s Global Digital Economy. She has completed over 50 senior level assignments in 29 countries within this practice, out of her total portfolio of over 600 assignments. Ms. Lune works extensively with FinTech clients from the Baltic sea region (Scandinavia, Baltics, Poland) and supports their global expansion plans in all continents by providing effective executive search solutions. As a team leader and regional director, she manages Pedersen & Partners teams in Poland, Baltics and Belarus. Her previous experience includes three years with the Stockholm School of Economics in Riga as the Executive MBA Program Director and six years with Shell in international and regional marketing management functions in Riga, Budapest, and Brussels.
Ms. Lune was a speaker at the CEE FutureTech congress in Warsaw - one of the most important business summits in Central and Eastern Europe and participated in Blockchain Pre-Accelerator Program at University of Latvia. She is also a blogger for RigaTechGirls, a Jury Member of CEE Capital Markets and FinTech Awards and a Contributing Advisor at the Digital Freedom Festival. Ms. Lune was recognized by Forbes as one of the top 25 most influential women in Latvia for two years in a row.

Pedersen & Partners is a leading international Executive Search firm. We operate 57 wholly owned offices in 53 countries across Europe, the Middle East, Africa, Asia & the Americas. Our values Trust, Relationship and Professionalism apply to our interaction with clients as well as executives. More information about Pedersen & Partners is available at www.pedersenandpartners.com

If you would like to conduct an interview with a representative of Pedersen & Partners, or have other media-related requests, please contact: Anastasia Alpaticova, Marketing and Communications Manager at: anastasia.alpaticova@pedersenandpartners.com

Global venture capital boom translates into new career opportunities for Life Sciences professionals in Europe

Venture capital (VC) is now a $155 billion annual industry worldwide, and over 10% of that worldwide VC funding is invested in Life Sciences. Biotech and pharmaceuticals in particular have seen massive increases, reaching a total of $16.6 billion in 2017. MedTech is rapidly catching up.

Recent shifts in the economic landscape make it clear that we are entering a new era of very large-scale VC activity worldwide. This has exciting implications for the global mobility of life sciences specialists.  

Firstly, although the US still raises the largest volume of VC funding according to the end-2017 figures, Asia and Europe are quickly increasing their respective shares of participation. VC has now become a truly global game.

Secondly, the entrance of new players is significantly changing the ways in which VC investment is approached. 2018 saw the launch of the largest VC fund in history: Japan’s $100 billion Softbank Vision Fund, four times larger than any previously existing fund. While Softbank is an outlier in terms of its sheer size, it exemplifies a trend which was already becoming apparent in the VC sector: a move towards much, much larger deals.

Thirdly, this new environment is creating a change in the way in which VC investors find enterprises for investment. Traditionally, entrepreneurs approached VC firms with proposals, but increasingly the pressure is now on the VC firms themselves to go out and find the next big thing before their competitors do. VC firms are increasingly roaming the world in active search of worthwhile investments and making the first contact on their own initiative.

For internationally mobile life sciences specialists, this could potentially mean the opening of enormous new vistas of opportunity. This is particularly true in Europe, where powerful research and development infrastructure coexists with a VC climate that has not yet fully matured. These larger VC funds are creating enormous employment booms in European cities with strong pre-existing life sciences innovation clusters.

Life sciences are already a huge employer in Europe, with the biotech sector alone already employing almost half a million people. The 2017 VC investment bounceback in Europe was a relief for many in the sector, and now the fully-recovered sector is already riding the first wave of ever-larger investments by ever-larger VC funds. The challenge, of course, is to predict exactly which countries and cities are likely to benefit most from this bullish new investment climate.

London, despite all the panic over the potential side effects of Brexit, is thus far retaining its position as the key destination for investment in life sciences, with no less than £1 billion flowing into the British capital last year. Certainly, plenty of unknowns remain within the black Brexit box, which could weaken London’s role. However, there is cause for optimism. Britain has long been seen as the most VC-friendly country in Europe, and it can be reasonably expected that maintaining a VC-friendly post-Brexit environment will merely not be a top priority, but the top priority.

Paris, meanwhile, is London’s most serious challenger for the position of Europe’s biotech capital. The full extent of French biotech’s ongoing 2018 bounceback from its 2016-2017 slump may yet surprise the world. In this new global VC climate of higher stakes and bigger deals, the biggest winners may be cities whose industries can think outside the box and create entirely new approaches to the sector, and Paris is emerging as such a city. For example, French VC giant Truffle Capital’s latest structural innovations include not only supporting start-ups financially, but supporting them in their research, through the fund’s purpose-built R&D department. The VC climate is evolving rapidly and is likely to favour climates which can foster business innovation as well as research innovation.

Berlin is unusual in that while it is certainly Germany’s capital of life sciences, regional centres of life sciences are much more evenly spread across the country - Mannheim, Bonn, Heidelberg and Martinsried are now all home to dynamic, fast-growing hubs of biotech start-ups. While smaller players in other countries may struggle to attract funding, Germany stands out as the country most likely to continually nurture entry-level innovation. Berlin and other German cities are emerging as global magnets for life sciences initiatives of all sizes: smaller companies attracted by generous state support, and larger, VC-backed companies attracted by the pool of high-level talent that the German government is actively investing in developing.

Britain, France and Germany are not the only European countries capable of hosting the next wave of life sciences. Netherlands is well positioned with the relocation of EMA from London to Amsterdam, and other authorities appear to be following.  Sweden and Spain also have fast-growing biotech sectors, located in Stockholm and Madrid. respectively. While these have not yet topped the $100 million VC investment mark, each has the levels of facilities to attract mega-fund interest if combined with attractive research proposals.  Only one thing is certain: life sciences specialists will very soon see an entirely new era of career opportunities emerge in Europe.


Lydia van der Meulen is a Client Partner at Pedersen & Partners, based in Amsterdam, the Netherlands. With her extensive search execution background in the Life Sciences, Industrial and Food industries, Mrs. van der Meulen brings to the firm two decades of end-to-end Executive Search project management expertise across Western and Central Europe, with occasional work in the USA, India, and China. Mrs. van der Meulen entered the Executive Search field in 1997 as European Search Director at the London office of a global boutique firm, specialised in Life Sciences & Industrial, for which she subsequently set up the Benelux office in 2002. As Managing Director, she grew and managed this steadily growing business to a team of four at its peak. From 2012 she continued as Managing Director for a global U.S. Executive Search firm and helped build their presence in Europe. Over the years Mrs. van der Meulen has conducted successful searches for start-ups, mid-sized organisations and multinationals, both publicly listed and privately held. Her experience includes: General Management, Human Resources, Sales & Marketing, Market Access, Public Affairs, Regulatory Affairs, Medical & Clinical, Quality, R&D, Manufacturing, and Technical Operations. Prior to joining the Executive Search sector, Mrs. van der Meulen worked in Management Consulting in London and Private Banking in the Netherlands.


Pedersen & Partners is a leading international Executive Search firm. We operate 56 wholly owned offices in 52 countries across Europe, the Middle East, Africa, Asia & the Americas. Our values Trust, Relationship and Professionalism apply to our interaction with clients as well as executives. More information about Pedersen & Partners is available at www.pedersenandpartners.com

If you would like to conduct an interview with a representative of Pedersen & Partners, or have other media-related requests, please contact: Anastasia Alpaticova, Marketing and Communications Manager at: anastasia.alpaticova@pedersenandpartners.com

Subscribe to Venture Capital